Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA+GD2 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Guangdong Clifford Hospital Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**PSMA+GD2 CAR-T cells** is an investigational autologous, fourth-generation dual-target CAR-T-cell therapy evaluated for refractory or relapsed glioma. It comprises genetically engineered T-cell products directed against prostate-specific membrane antigen and disialoganglioside GD2, administered intravenously to recognize antigen-positive glioma cells and induce T-cell-mediated cytotoxicity. In the registered ChiCTR2000035410 study at Guangdong Clifford Hospital, the combined PSMA CAR-T and GD2 CAR-T treatment was studied in patients with refractory or relapsed glioma; a subsequent six-patient report described a 50% objective response rate, grade 1 cytokine-release syndrome in three patients, and no immune effector cell-associated neurotoxicity. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=57260))
- Other names
- PSMA+GD2 CAR T cellsPSMA+GD2 CAR T 细胞autologous PSMA+GD2 CAR T cells
02
Targets
GD2PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA+GD2 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA+GD2 CAR-T cells.